智通财经APP获悉，大和发布研究报告称，维持百济神州(06160)“买入”评级，目标价由162港元升至171港元。该行预计，在Brukinsa销售带动下，百济神州去年第四季营收同比增长65%至 10.45亿美元。预计研发成本同比增加10%至5.45亿美元。
大和表示，上调对Brukinsa预测，2025和2026年营收预测各升7%/4%至35亿美元/42亿美元，主要是由于其在美国和欧洲的销售额增加，以及其在全球布鲁顿氏酪氨酸激酶(BTK)市场的一流的产品和持续的市场占有率提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.